Formulary Search
A to Z of Drugs : M
Show Icon and Status Keys
- Not Specified
NHSE commissioned services only. No Surrey Heartlands Trusts are commissioned to provide this.
- Powder
For agents not bound by activated charcoal e.g. iron, lithium, bodypackers
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
- Sachets (powder)
Prescribing in primary care on specialist recommendation
- Chewable tablets
Prescribing in primary care on specialist recommendation
- Oral suspension
- Injection
- Intravenous injection (IV)
- Oral suspension
- Intravenous infusion
- Liquid
Second line treatment option for scabies. Permethrin cream / rinse or ivermectin tablets are preferred treatment options for scabies.
- Intravenous infusion
- Not Specified
Intravenous solution diluted and given orally
- Capsules
No local trust is a NHSE commissioned specialist cardiac centre
- Powder
Prescribe on advice from specialist e.g. dietitian
- Powder
Prescribe on advice from specialist e.g. dietitian
- Chewable tablets
- Suspension
- Tablets
- Capsules (slow release)
- Tablets
1st month supply from specialist team before request for primary care prescribing
- Injection
Sayana Press
Patients may be trained to self-administer Sayana Press
- Pre-filled syringe
Depo Provera
CSM advice: Depo-Provera should only be used when other methods of contraception are inappropriate. Benefits of using medroxyprogesterone acetate beyond 2 years should be evalated against risk.
Women with risk factors for osteoporosis should consider alternative methos of contraception.
- Tablets
1st month supply from specialist team before request for primary care prescribing
- Tablets
- Tablets
- Tablets
Off-label use. Hot flushes caused by long-term androgen suppression in men with prostate cancer
1st month supply from specialist team before request for primary care prescribing
- Tablets
- Capsules
- Tablets
- Oral suspension
- Capsules
- Tablets
- Oral suspension
See separate entry for use in menorrhagia and dysmenorrhoea.
Non-formulary.
Prophylaxis of malaria is not to be prescribed on the NHS.
- Tablets
Off-label use. On recommendation of palliative care team.
- Tablets
1st month supply from specialist team before request for primary care prescribing
- Modified release tablets
- Not Specified
- Modified release tablets
ONLY for patients OVER 55 YEARS (without neurodevelopmental disorders)
Maximum 13 weeks treatment
Melatonin 2mg MR tablets are the recommended preferred 1st line product
Prescribe generically. Circadin is NON-FORMULARY
- Immediate release tablets
ONLY for patients OVER 55 YEARS (without neurodevelopmental disorders)
Maximum 13 weeks treatment
If immediate onset of action is required or crushed to aid swallowing
- Oral solution
ONLY for patients OVER 55 YEARS (without neurodevelopmental disorders)
Maximum 13 weeks treatment
Reserved ONLY if feeding tube in situ, or significant swallowing difficulties, and the use of the whole or crushed tablets are unsuitable
- Not Specified
ONLY for patients OVER 55 YEARS (without neurodevelopmental disorders)
Maximum 13 weeks treatment
All formulations of melatonin for adults under 55 without neurodevelopmental disorders were agreed by APC as NON-FORMULARY
- Capsules
ONLY for patients OVER 55 YEARS (without neurodevelopmental disorders)
Maximum 13 weeks treatment
Not a cost effective option
- Not Specified
- Modified release tablets
Rapid eye movement sleep behaviour disorder. (RBD)
On specialist recommendation
Melatonin 2mg MR tablets are the recommended preferred 1st line product
Prescribe generically. Circadin is NON-FORMULARY
- Immediate release tablets
Rapid eye movement sleep behaviour disorder. (RBD)
If immediate onset of action is required or crushed to aid swallowing
On specialist recommendation
- Oral solution
Rapid eye movement sleep behaviour disorder. (RBD)
Reserved ONLY if feeding tube in situ, or significant swallowing difficulties, and the use of the whole or crushed tablets are unsuitable
On specialist recommendation
- Capsules
Rapid eye movement sleep behaviour disorder. (RBD)
- Oral solution
For inducing sleep in people requiring an EEG or audiology testing
- Modified release tablets
Prescribing for adults with neurodevelopmental disorders in Primary Care - only on recommendation from the specialist mental health team.
Prescribing in Primary Care may be undertaken on recommendation from the specialist mental health team.
Note the change from previous Amber status (which required shared-care). Formal melatonin shared care is no longer required for this indication.
- Immediate release tablets
Prescribing for adults with neurodevelopmental disorders in Primary Care - only on recommendation from the specialist mental health team.
Immediate release tablets may be crushed for administration (licensed use).
- Oral solution
Prescribing for adults with neurodevelopmental disorders in Primary Care - only on recommendation from the specialist mental health team.
1mg/ml oral solution sugar free - restricted to patients with significant swallowing difficulties or a feeding tube in situ.
- Immediate release tablets
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
Immediate release tablets may be crushed for administration (licensed use)
- Oral solution
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
1mg/ml oral solution sugar free - restricted to prescribing for people with significant swallowing difficulties or a feeding tube in situ
- Modified release tablets
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
2mg modified release tablets.
- Modified release tablets
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
2mg MR tablets are preferred.
- Immediate release tablets
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
Immediate release tablets may be crushed for administration (licensed use)
- Oral solution
Initiation and stabilisation for at least 1 month by the mental health specialist team before any request to transfer prescribing to Primary Care.
More detail and resources are provided on the PAD page (accessed by clicking the drug name).
1mg/ml oral solution sugar free.
Restricted to prescribing for people with significant swallowing difficulties or a feeding tube in situ
- Tablets
Not a preferred NSAID, limited place in therapy.
ASPH - restricted to rheumatology only.
- Oral solution
- Oro-dispersible tablets
- Tablets
As combination therapy - Appropriate for Primary Care initiation when being added to existing AChE inhibitor therapy in patients with worsening cognitive function or other markers of deterioration.
Reserve orodispersible tablets and oral solution for patients who are unable to swallow tablets.
- Oral solution
- Oro-dispersible tablets
- Tablets
As monotherapy in patients with severe Alzheimer's or in moderate disease where an AChE is not tolerated.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Not Specified
- Oral solution
- Oro-dispersible tablets
- Tablets
In Lewy Body dementia if AChE inhibitors are contraindicated or not tolerated. Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Oral solution
- Oro-dispersible tablets
- Tablets
In Parkinson's dementia if AChE inhibitors are contraindicated or not tolerated. Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Oral solution
- Oro-dispersible tablets
- Tablets
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Not Specified
- Tablets
On advice from specialist.
NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g. Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency
- Not Specified
- Injection
- Injection
- Cream
1% menthol in aqueous cream.
- Cream
5% menthol in aqueous cream - on recommedation from specialist team
- Cartridges
- Injection
Mepivivacaine 30mg per mL
- Cartridges
- Injection
ASPH restrict to dental anaesthesia and chiropody.
SASH for colposcopy only (separate formulary entry)
- Not Specified
- Intramuscular injection (IM)
- Tablets
- Oral suspension
- Tablets
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral suspension
- Tablets
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral suspension
- Tablets
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Lozenges
- Lozenges
- Injection
- Intravenous infusion
Restricted for Microbiology Approval Only
- Gastro-resistant tablets
- Suppositories
- Modified release tablets
- Granules (slow release)
- Modified release tablets
- Enema
- Foam enema
- Gastro-resistant tablets
- Intravenous injection (IV)
- Tablets
- Intravenous infusion
- Intravenous injection (IV)
- Modified release tablets
- Tablets
NOTE: 1g ordinary tablets are disproportionately expensive in primary care. 1g modified release tablets are recommended.
- Oral solution
- Powder
- Tablets
Not a cost-effective option. Prescribe as separate components.
- Tablets
- Tablets
Sitagliptin is the preferred DPP4. Reserve combination products for patients in whom separate components are less appropriate. Existing patients would not be expected to change therapy unless appropriate to do so.
- Oral solution
Restricted to Drugs & Alcohol Service only.
- Tablets
For substance misuse service only - e.g. for holiday travel.
Review risk of patient crushing and injecting tablets before prescribing.
- Oral solution
Palliative care teams only. Caution when converting from other opioids.
- Subcutaneous infusion
Palliative care teams only. Caution when converting from other opioids.
- Tablets
For prevention of recurrent UTI in women over the age of 16 who are not pregnant
- Tablets
Prescribe on specialist team recommendation for the following patient cohorts
- recurrent UTI of unknown cause
- recurrent UTI and suspected cance
- recurrent upper UTI
- recurrent lower UTI in: men, trans women and non-binary people with a male genitourinary system, who are aged 16 and over
- pregnant women, and pregnant trans men and non-binary people
- children and young people.
- Tablets
Option for non-scarring alopecia
- Oral solution
- Subcutaneous infusion
- Tablets
For adults see methotrexate -dematology indications
For severe atopic dermatitis in children from age 2 to 16 years under paediatric dermatology specialist only
- Injection
- Tablets
Weekly dosing. Tablets - only to prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Injection
- Tablets
DO NOT prescribe or supply 10mg tablets. WEEKLY dose frequency. Advise patients to carry the patient alert card / book
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Intramuscular injection (IM)
- Injection
- Tablets
Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets. WEEKLY dosing.
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Injection
- Tablets
WEEKLY dosing. Only 2.5mg tablets to be prescribed. DO NOT prescribe or supply 10mg tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Injection
- Tablets
- Injection
- Tablets
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Injection
- Tablets
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Inhalation
Acute, trauma pain.
RSFT - for
- Use during removal of brachytherapy
- Transperineal prostate biopsies
- Pain management by the acute pain team for adult non-obstetric patients
- Procedural pain relief in gynaecological outpatients excluding obstetrics or paediatrics patients
- Pain management during invasive procedures undertaken in the radiology suite
- Gel
For photochemotherapy by dermatology ONLY
- Lotion
- Tablets
For photochemotherapy by dermatology ONLY
- Spray
- Cream
Dermatology only - for use with photodynamic therapy
- Tablets
- Injection
- Modified release tablets
18mg, 27mg, 36mg, 54mg: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Adult ADHD - to be diagnosed, initiated and stabilised on ADHD medication by a SABP specialist before shared-care can be requested.
See PAD entry for current shared care document "CNS stimulants in ADHD shared care - May 2016"
Patients transitioning from children's services can continue to be managed under existing arrangements
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Immediate release tablets
- Oral solution
Adult ADHD - to be diagnosed, initiated and stabilised on ADHD medication by a SABP specialist before shared-care can be requested.
See PAD entry for current shared care document "CNS stimulants in ADHD shared care - May 2016"
Patients transitioning from children's services can continue to be managed under existing arrangements.
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
Adult ADHD - to be diagnosed, initiated and stabilised on ADHD medication by a SABP specialist before shared-care can be requested.
See PAD entry for current shared care document "CNS stimulants in ADHD shared care - May 2016"
Patients transitioning from children's services can continue to be managed under existing arrangements
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
Modified-release: Prescribe by brand. Xaggitin XL and Affenid XL are the locally agreed brands with stock availability.
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Tablets
RSFT only
- Tablets
- Intramuscular injection (IM)
Methylprednisolone acetate (Depo-Medrone)
- Intravenous infusion
- Intravenous injection (IV)
Methylprednisolone sodium succinate (Solu-Medrone)
- Intravenous infusion
- Tablets
- Intra-articular injection
as Methylprednisolone ACETATE (Depo-medrone)
- Intratympanic injection
- Intra-ocular injection
- Intra-articular injection
- Injection
Methylene Blue - Off-label. Septic shock, refractory shock.
- Intravenous injection (IV)
- Oral solution
- Tablets
- Injection
- Oral solution
- Tablets
- Subcutaneous infusion
- Injection
- Tablets
- Tablets
- Oral solution
- Tablets
- Tablets
- Tablets
- Tablets
- Tablets
- Injection
- Tablets
- Oral solution
- Tablets
- Infusion
- Suppositories
- Gel
- Vaginal gel
- Tablets
- Gel
Alternative treatment if ivermectin not available or inappropriate as per CKS.
0.75% gel
- Cream
Alternative treatment if ivermectin not available or inappropriate as per CKS.
0.75% cream
- Capsules
Under specialist supervision in hospital.
- Capsules
- Capsules
Cardiology specialists only.
Namuscla brand is non-preferred for this indication
- Capsules
- Intravenous infusion
- Cream
2nd line - Epimax Oatmeal Cream is preferred.
Consider if self-care is appropriate
- Lotion
Consider if self-care is appropriate
- Cream
- Powder
Note potential serious interaction with warfarin and topical miconazole preparations.
Available to purchase from a pharmacy if patient is suitable for self-care.
See separate entry for oral candidiasis: Miconazole - Oral candidiasis - surrey.res.services
- Spray
Note potential serious interaction with warfarin and topical miconazole preparations.
Available to purchase from a pharmacy if patient is suitable for self-care.
- Oromucosal gel
Note potential serious interaction with warfarin and topical miconazole preparations (including oral gel).
- Oromucosal solution
- Subcutaneous infusion
- Subcutaneous injection (sc)
- Injection
- Oral solution
ASPH - Paediatrics (using an unlicensed liquid preparation)
SASH - Children aged from 6 months to 14 years for:
- Sedation and anxiolysis prior to diagnostic, surgical, therapeutic or endoscopic procedures.
- premedication before induction of general anaesthesia.
SASH - in adults for:
-premedication before induction of general anaesthesia
- adult dental procedures
- Intravenous infusion
- Pre-filled oral syringe
- Liquid
- Injection
SASH - alternative to lorazepam for patients with decomensated liver disease.
- Pre-filled oral syringe
- Liquid
- Intranasal administration
Unlicensed.
SASH - restricted to Adults Special Care Dentistry. Refer to dental protocol - sedation for patients with special needs. [Specials order from Guy's and St Thomas']
- Tablets
Off-label use. Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
See separate entry for use in orthostatic hypotension
- Tablets
Postural hypotension in Parkinson's disease or due to autonomic dysfunction.
Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
- Not Specified
- Tablets
- Injection
- Injection
- Injection
Off-label use. For ITU administration via nebuliser system.
- Not Specified
- Modified release tablets
- Tablets
- Tablets
Option for scarring / non-scarring alopecia
- Foam
- Topical solution
Available to purchase over the counter (OTC) for self-care.
- Not Specified
- Tablets (slow release)
- Intravenous infusion
- Subcutaneous injection (sc)
For UC & CD. Adults only.
- Oro-dispersible tablets
- Tablets
- Oral solution
Liquid formulation is not cost effective; consider orodispersible tablets.
- Tablets
- Tablets
- Tablets
Administered sublingually or rectally
- Vaginal tablets
Vaginal tablets administered rectally.
- Vaginal tablets
- Not Specified
- Not Specified
- Not Specified
- Not Specified
- Eye drops (preservative free)
- Subconjunctival injection
- Intravenous injection (IV)
Licensed mivacurium injections are scheduled for discontinuation by May 2026.
- Not Specified
- Tablets
Initiation and stabilisation by specialist for a minimum of 6 months before any transfer of prescribing responsibility is requested.
- Tablets
- Tablets
- Tablets
- Tablets
- Powder
Prescribe on advice from specialist e.g. dietitian
- Capsules
Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service.
Hospital inpatients - as per local hospital guidelines
- Nasal spray
Recommended 1st line treatment option
- Scalp application
0.1% scalp lotion
- Cream
- Ointment
0.1% potent
Least cost-effective. Consider an alternative potent topical steroid (betamethasone or fluocinolone)
- Nasal spray
- Inhaler (dry powder)
Specialist* recommendation only. Used in severe asthma.
* a healthcare professional with higher training in respiratory medicine and proficeincy in the management of asthma
Only triple therapy DPI licensed for asthma.
Prescribe by BRAND
- Nasal spray
- Solution
- Chewable tablets
- Sachets (granules)
- Tablets
- Chewable tablets
- Sachets (granules)
- Tablets
Off-label use.
For use if there is an inadequate response to increased dose antihistamine treatment.
- Oral drops
- Gel
Unlicensed product.
Morphine 10mg in 10ml of Intrasite gel (0.1%).
- Immediate release tablets
- Oral solution
- Oro-dispersible tablets
- Modified release capsules
- Modified release tablets
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
- Capsules (slow release)
- Granules (slow release)
- Tablets (slow release)
- Immediate release tablets
- Oral solution
- Oro-dispersible tablets
- Injection
- Solution for infusion
- Suppositories
- Immediate release tablets
- Oral solution
- Oro-dispersible tablets
- Subcutaneous infusion
- Subcutaneous injection (sc)
- Modified release capsules
- Modified release tablets
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
- Mouthwash
- Eye drops
- Tablets
- Tablets
- Tablets
NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g. Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency
- Nasal ointment
- Cream
- Ointment
- Nasal ointment
- Capsules
- Oral suspension
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
Prescribe generically (except in transplant indications)
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Gastro-resistant tablets
- Oral suspension
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Capsules
- Oral suspension
- Tablets
For EXISTING patients: GPs may continue to prescribe for existing post-transplant patients only. NHS England are looking to repatriate these patients in the future. GPs must not accept any new requests to prescribe for new patients.
- Capsules
- Oral suspension
- Tablets
- Capsules
- Gastro-resistant tablets
- Oral suspension
- Tablets
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Tablets
FOR EXISTING PATIENTS only:
GPs may continue to prescribe for existing post-transplant patients only.
NHS England are looking to repatriate these patients in the future. GPs must not accept requests to prescribe for new patients.
- Not Specified
FOR NEW PATIENTS: RED drug for post-transplant. Funded via NHS England.
GPs should not accept any new request to start prescribing mycophenolic acid post-transplant.
- Gel
2nd line - Epimax Isomol Gel is preferred.
Consider if self-care is appropriate.